Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 InfectionA Randomized Controlled Trial | Zendy

Roy M. Gulick | Zendy

Open Access

Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Author(s) -

Roy M. Gulick

Publication year - 2006

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.296.7.769

Subject(s) - medicine , efavirenz , zidovudine , lamivudine , regimen , abacavir , hazard ratio , placebo , randomized controlled trial , viral load , confidence interval , immunology , human immunodeficiency virus (hiv) , viral disease , virus , antiretroviral therapy , hepatitis b virus , alternative medicine , pathology

Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research